drugset / Trial / NCT01878695
Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer
Phase 1
Completed
13 enrolled
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NaSingle-groupOpen-labelTreatment
Summary
NAC is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement and also is available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. In the exercise physiology literature, both oral and injectable NAC have been shown to reduce fatigue and improve recovery from exertion which has interesting implications for exploring cancer-related fatigue. In terms of cancer cell biology, reactive oxygen species (ROS) may play an important role in the development and progression of breast cancer
Timeline
- Start
- 2012-07-26
- Primary completion
- 2015-05-14
- Completion
- 2015-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-acetylcysteine | Small molecule | 50 mg/kg | Intravenous |
| Subject | N-acetylcysteine | Small molecule | 150 mg/kg | Intravenous |
| Subject | N-acetylcysteine | Small molecule | 600 mg | Intravenous |